GlassScriptPhysician profile
Teyanna Joyce Dillingham
NPI 1467925206
$1,450.39
in general payments reported to CMS, 2019-2025
23 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $39.52 · 2023: $493 · 2024: $425 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,410.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $573.34 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $120.86 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $97.34 | 2024-2025 | Auvelity |
| Novo Nordisk INC | $77.03 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Vanda Pharmaceuticals INC. | $65.66 | 2025 | Hetlioz, Fanapt |
| Alkermes, INC. | $64.23 | 2023-2024 | Vivitrol, Vivitrol |
| Neurocrine Biosciences, INC. | $52.65 | 2025 | |
| Gilead Sciences, INC. | $48.41 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.11 | 2022-2025 | Caplyta |
| Amgen INC. | $43.85 | 2023-2025 | Repatha, Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $30.78 | 2023 | Rexulti, Abilify Maintena |
| Inari Medical, INC. | $29.99 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Janssen Pharmaceuticals, INC | $29.91 | 2023 | Invega Trinza, Invega Sustenna |
| Edwards Lifesciences Corporation | $21.04 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Glaxosmithkline, LLC. | $19.75 | 2025 | Pediarix, Bexsero, Penmenvy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $18.61 | 2023 | Trintellix |
| Pfizer INC. | $17.68 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $17.48 | 2025 | Farxiga |
| Indivior INC. | $15.90 | 2025 | Sublocade |
| Corium, LLC | $15.80 | 2023 | Azstarys |
| Exact Sciences Corporation | $14.96 | 2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $13.58 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $13.43 | 2024 | Proquad, Vaxelis, Gardasil |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teyanna Dillingham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.